THE IMPACT OF ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECOA) ON ALZHEIMER’S DISEASE CLINICAL TRIAL DATA QUALITY

2017 ◽  
Vol 13 (7) ◽  
pp. P935
Author(s):  
H. Todd Feaster ◽  
Todd M. Solomon ◽  
Danielle Abi-Saab ◽  
Annamarie Vogt ◽  
Jordan M. Barbone ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Clinical Outcome ◽  
Data Quality ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Outcome Assessments ◽  
Clinical Outcome Assessments ◽  
The Impact

scholarly journals Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Kasia Lobello ◽  
J. Michael Ryan ◽  
Enchi Liu ◽  
Gregory Rippon ◽  
Ronald Black
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Clinical Review ◽  
Clinical Trial Data ◽  
Beta Amyloid ◽  
Trial Data ◽  
Significant Progress ◽  
Amyloid A ◽  
The Past

As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data.

Donepezil 23 mg: Is it more advantageous compared to the original?

2012 ◽  
Vol 1 (11) ◽  
pp. 272-273 ◽  
Author(s):  
Clayton English
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Sustained Release ◽  
Dosage Form ◽  
Acetylcholinesterase Inhibitor ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Clinical Use

The acetylcholinesterase inhibitor donepezil has been in clinical use for the treatment of Alzheimer's disease since 1996. The patent on the medication expired in November 2010, and at approximately the same time, a new dosage form of donepezil was FDA approved for moderate to severe Alzheimer's disease. This article discusses the benefits and risks of the new 23 mg sustained-release dosage form compared with donepezil 10 mg, based on the clinical trial data.

scholarly journals Setting the IMPACT (IMProve Access to Clinical Trial data) Observatory baseline

2018 ◽  
Vol 28 (1) ◽  
Author(s):  
Mersiha Mahmić-Kaknjo ◽  
Josip Šimić ◽  
Karmela Krleža-Jerić
Keyword(s):  
Clinical Trial ◽  
Clinical Trial Data ◽  
Trial Data ◽  
The Impact ◽  
Improve Access
Sign in / Sign up

Export Citation Format

Share Document